Veracyte Q3 2024 Earnings Report $39.18 -1.87 (-4.56%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Veracyte EPS ResultsActual EPS$0.19Consensus EPS $0.03Beat/MissBeat by +$0.16One Year Ago EPS-$0.03Veracyte Revenue ResultsActual Revenue$115.86 millionExpected Revenue$109.81 millionBeat/MissBeat by +$6.05 millionYoY Revenue Growth+28.60%Veracyte Announcement DetailsQuarterQ3 2024Date11/6/2024TimeAfter Market ClosesVCYT Upcoming EarningsVeracyte will be holding an earnings conference call on Monday, February 24 at 4:30 PM Eastern. Interested parties can register for or listen to the call. Conference Call ResourcesConference CallConference Call TranscriptSEC FilingVCYT Earnings History Veracyte Earnings HeadlinesVeracyte, Inc.February 21 at 7:07 PM | cnn.comAnalysts Set Veracyte, Inc. (NASDAQ:VCYT) Price Target at $42.00February 21 at 1:19 AM | americanbankingnews.comNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.February 22, 2025 | Brownstone Research (Ad)Veracyte Inc (VCYT) Announces Participation in Key Investor ConferencesFebruary 20 at 9:13 PM | gurufocus.comVeracyte to Participate in Upcoming Investor ConferencesFebruary 19 at 5:05 PM | businesswire.comVeracyte (NASDAQ:VCYT) Lowered to "Hold" Rating by StockNews.comFebruary 19 at 1:57 AM | americanbankingnews.comSee More Veracyte Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Veracyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veracyte and other key companies, straight to your email. Email Address About VeracyteVeracyte (NASDAQ:VCYT) engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.View Veracyte ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Hims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
